Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) was the target of a large drop in short interest in August. As of August 31st, there was short interest totalling 20,800 shares, a drop of 11.9% from the July 31st total of 23,600 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average trading volume of 244,900 shares, the days-to-cover ratio is presently 0.1 days.

An institutional investor recently bought a new position in Hancock Jaffe Laboratories stock. Jane Street Group LLC bought a new position in Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 77,915 shares of the company’s stock, valued at approximately $81,000. Jane Street Group LLC owned 0.43% of Hancock Jaffe Laboratories as of its most recent SEC filing. Institutional investors own 1.29% of the company’s stock.

Shares of Hancock Jaffe Laboratories stock traded down $0.01 during midday trading on Friday, hitting $0.96. The company’s stock had a trading volume of 84,373 shares, compared to its average volume of 47,197. The stock has a 50-day simple moving average of $1.03 and a 200-day simple moving average of $1.51. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.46 and a current ratio of 2.46. Hancock Jaffe Laboratories has a 1-year low of $0.87 and a 1-year high of $3.45.

Hancock Jaffe Laboratories (NASDAQ:HJLI) last issued its earnings results on Monday, August 5th. The company reported ($0.13) EPS for the quarter. Hancock Jaffe Laboratories had a negative return on equity of 207.10% and a negative net margin of 5,250.79%.

HJLI has been the subject of several research reports. ValuEngine lowered Hancock Jaffe Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, September 4th. Maxim Group reissued a “buy” rating and set a $3.00 price objective on shares of Hancock Jaffe Laboratories in a research note on Thursday, August 15th. Finally, Zacks Investment Research lowered Hancock Jaffe Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, June 26th.

Hancock Jaffe Laboratories Company Profile

Hancock Jaffe Laboratories, Inc, a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease.

Featured Article: Preferred Stock

Receive News & Ratings for Hancock Jaffe Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hancock Jaffe Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.